OKYO vs. CLLS, VXRT, CRDF, MOLN, BCDA, VIGL, LIFE, SGMO, OMGA, and DBVT
Should you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include Cellectis (CLLS), Vaxart (VXRT), Cardiff Oncology (CRDF), Molecular Partners (MOLN), BioCardia (BCDA), Vigil Neuroscience (VIGL), aTyr Pharma (LIFE), Sangamo Therapeutics (SGMO), Omega Therapeutics (OMGA), and DBV Technologies (DBVT). These companies are all part of the "biological products, except diagnostic" industry.
OKYO Pharma (NASDAQ:OKYO) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, community ranking, earnings, valuation, risk and media sentiment.
OKYO Pharma has a net margin of 0.00% compared to Cellectis' net margin of -529.81%. OKYO Pharma's return on equity of 0.00% beat Cellectis' return on equity.
OKYO Pharma has a beta of 0.03, suggesting that its stock price is 97% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.08, suggesting that its stock price is 208% more volatile than the S&P 500.
OKYO Pharma has higher earnings, but lower revenue than Cellectis.
OKYO Pharma currently has a consensus target price of $7.00, indicating a potential upside of 369.80%. Cellectis has a consensus target price of $8.50, indicating a potential upside of 213.65%. Given OKYO Pharma's higher possible upside, analysts plainly believe OKYO Pharma is more favorable than Cellectis.
3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Cellectis received 401 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 100.00% of users gave OKYO Pharma an outperform vote while only 67.95% of users gave Cellectis an outperform vote.
In the previous week, Cellectis had 10 more articles in the media than OKYO Pharma. MarketBeat recorded 12 mentions for Cellectis and 2 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 1.19 beat Cellectis' score of 0.58 indicating that OKYO Pharma is being referred to more favorably in the media.
Summary
OKYO Pharma beats Cellectis on 8 of the 14 factors compared between the two stocks.
Get OKYO Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OKYO Pharma Competitors List
Related Companies and Tools
